Fat buildup inside lung immune cells may be what starts pulmonary fibrosis, mouse study finds
A UCLA Health-led team reports that a cholesterol imbalance inside alveolar macrophages can trigger the fibrotic cascade in mice before any scarring appears, pointing to a new, earlier step in a disease that affects roughly 100,000 Americans.

Researchers led by a UCLA Health physiologist have traced a possible trigger for pulmonary fibrosis, the scarring lung disease that has no cure, to a fat imbalance inside a type of immune cell that patrols the lung's air sacs. The finding, drawn entirely from experiments in mice, points to an earlier starting point for the disease than the fibrosis-forming cells that have been the usual focus of research.
The study, led by Elizabeth Tarling, a professor of cardiology in UCLA's Department of Medicine, was published this fall in the American Journal of Respiratory Cell and Molecular Biology and described in a university news release on November 9. The work, also distributed through EurekAlert and picked up by outlets including News-Medical, centers on alveolar macrophages, immune cells that normally clear debris and dead cells from the lungs and help repair tissue after injury.
A fat imbalance that comes first
The researchers worked with mice engineered to lack ABCG1, a protein that pumps excess cholesterol out of cells. Without it, alveolar macrophages in the mice began accumulating lipids, particularly cholesterol and certain polyunsaturated fats, rapidly and well before any other changes appeared in the lungs. Fibrosis, measured as collagen buildup and tissue remodeling, showed up only afterward.
Lipid profiling of the overloaded macrophages, and separately of macrophages taken from mice in the earliest stages of ordinary fibrosis, turned up the same pattern of fat accumulation in both cases. When the team exposed lung fibroblasts, the cells that lay down scar tissue, to the accumulated lipids in laboratory dishes, the fibroblasts activated and ramped up genes associated with fibrosis. The authors describe the result in their paper as a lipid-mediated signal passing from an overloaded macrophage to a neighboring fibroblast, switching it into a scar-producing state.
Two further experiments tested whether the lipid imbalance was not just associated with fibrosis but actually caused it. Restoring normal cholesterol handling in macrophages, by transplanting bone marrow containing working ABCG1 into the mutant mice, nearly fully protected them from developing fibrosis. Conversely, transplanting ABCG1-deficient bone marrow into otherwise normal mice was enough on its own to bring on fibrosis, even though every other cell in those animals had a fully functional lipid-export system. Blocking fibroblasts' uptake of the lipids in question also prevented the scarring response, the paper reports.
"Macrophage cholesterol dysregulation is sufficient to initiate spontaneous lung fibrosis," the authors conclude in the paper, describing what they call a lipid-mediated macrophage-fibroblast axis as a previously unrecognized driver of the disease.
An understudied disease with few treatments
Pulmonary fibrosis covers a group of lung diseases in which scar tissue gradually stiffens and thickens the lungs, making breathing progressively harder. According to the National Heart, Lung, and Blood Institute, roughly 13 to 20 people out of every 100,000 worldwide have the disease, including about 100,000 Americans, a figure the institute's researchers derived from a review of more than 4,700 adults living with the condition. Idiopathic pulmonary fibrosis, the most common form, has no identified cause and is generally considered progressive and eventually fatal; existing medications can slow its advance but do not reverse scarring that has already formed or restore lung tissue once it is lost.
Because effective treatments remain scarce, researchers have spent years trying to pin down what actually starts the fibrotic process in the lung, as opposed to what sustains or accelerates it once scarring is under way. Fibroblasts, the cells that physically deposit collagen, have drawn the most attention as both the visible culprits and the primary drug target. The new study instead puts an upstream cell, the alveolar macrophage, and a basic metabolic housekeeping function, lipid export, at the start of the chain, with the fibroblast activation it describes coming only as a downstream consequence.
That reframing matters for who might eventually be affected by any treatment that comes out of this line of research: patients whose disease is caught at a genetic-risk or pre-symptomatic stage, before conventional measures of fibrosis such as collagen buildup or stiffened lung tissue would show up on a scan or a biopsy. The paper's authors write that detecting abnormal lipid handling in a patient's macrophages, if it can be done reliably, might flag elevated risk earlier than current diagnostic methods allow.
Caution, and what comes next
The authors and outside science writers covering the release were careful to frame the results as preclinical. Every experiment described in the paper was conducted in mice carrying an engineered genetic deletion, not in human lung tissue or human patients, and no human trial has been proposed or registered based on these findings. Whether the same ABCG1-dependent, lipid-driven pathway operates in people with sporadic, non-genetic pulmonary fibrosis, which accounts for the large majority of human cases, has not yet been tested.
Co-authors on the paper, in addition to Tarling, include researchers from UCLA and collaborating institutions: Elizabeth F. Redente, Isaiah Little, Marissa O'Callaghan, Lucas Dantas, Michelle Steel, Angela Cheng, Elinor Lee, Richard L. Watson, Kevin J. Williams, Michael P. Keane, James P. Bridges, Alexandra L. McCubbrey, Thomas Q. de Aguiar Vallim and Cormac McCarthy. Little and O'Callaghan are listed as having contributed equally to the work.
The authors point to two possible follow-on directions rather than an immediate therapy. One is pharmacological: drugs that either preserve or restore normal lipid handling inside macrophages, or that block fibroblasts from taking up the lipids that switch them into a scar-forming state, could in principle interrupt the process before fibrosis becomes established. The other is diagnostic, using early lipid abnormalities in macrophages, if they can be measured in accessible samples such as blood or airway fluid, as a warning sign in people at elevated risk, including those with a family history of the disease or known genetic risk factors, well before symptoms or imaging changes appear.
- Mice lacking the cholesterol-transport protein ABCG1 developed fat buildup in lung immune cells before any fibrosis appeared.
- Restoring normal lipid handling in those cells, via bone marrow transplant, nearly fully prevented fibrosis in the mice.
- Transplanting the defective cells into otherwise healthy mice was sufficient on its own to trigger fibrosis.
- Pulmonary fibrosis affects an estimated 100,000 Americans and has no cure, according to the National Heart, Lung, and Blood Institute.
Neither the university release nor the paper's abstract reports a timeline for testing any resulting compound in animals with naturally occurring fibrosis, let alone in humans. The researchers describe their work as establishing a mechanism and a potential target, leaving the translation into a usable drug or diagnostic test, and the much larger task of confirming the pathway in human disease, for future studies.

Europe's Hera Probe Sends Back First Close-Up Images of Asteroid DART Deliberately Struck
Thousands of tiny animals found living inside deep-sea mining's target rocks

Scientists May Have Solved the 40-Year Mystery Behind Uranus and Neptune's Lopsided Magnetic Fields
